Negative symptoms in schizophrenia – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:14:43 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Negative symptoms in schizophrenia – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on Esketamine and Diphenhydramine for Treating Depression and Negative Symptoms in Schizophrenia Patients https://clinicaltrials.eu/trial/study-on-esketamine-and-diphenhydramine-for-treating-depression-and-negative-symptoms-in-schizophrenia-patients/ Wed, 29 Apr 2026 15:03:26 +0000 https://clinicaltrials.eu/trial/study-on-esketamine-and-diphenhydramine-for-treating-depression-and-negative-symptoms-in-schizophrenia-patients/ This clinical trial is focused on studying the effects of esketamine on patients with schizophrenia or schizoaffective disorder, specifically targeting negative and depressive symptoms. Esketamine is a medication that will be compared to a placebo to see if it can better reduce these symptoms. The study aims to determine if esketamine is more effective than the placebo in improving the mental health of individuals with these conditions.

Participants in the study will receive treatments over a period of time, with some receiving esketamine and others receiving a placebo. The placebo used in this study is diphenhydramine, which is commonly known for its use in allergy relief. The study will monitor changes in symptoms using specific scales designed to measure negative and depressive symptoms in schizophrenia and schizoaffective disorder.

The trial will involve a series of treatments and assessments to track the progress of participants. The goal is to observe any changes in symptoms from the beginning of the study to the end, providing valuable information on the effectiveness of esketamine as a treatment option for these mental health conditions. The study is expected to continue until November 2025.

]]>